BEAMTREE HOLDINGS LIMITED (BMT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BMT - BEAMTREE HOLDINGS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -2.61
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.245

20 Nov
2024

0.000

OPEN

$0.23

0.000

HIGH

$0.25

997,905

LOW

$0.23

TARGET
$0.70 185.7% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
BMT: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.8 - 0.5 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx27.6 M
Book Value Per Share xxxxxxxxxxxxxxx16.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-0.5 M
Net Profit Margin xxxxxxxxxxxxxxx-18.50 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-10.82 %
Return on Invested Capital xxxxxxxxxxxxxxx-10.60 %
Return on Assets xxxxxxxxxxxxxxx-8.36 %
Return on Equity xxxxxxxxxxxxxxx-10.82 %
Return on Total Capital xxxxxxxxxxxxxxx-12.56 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-0.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx31 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx5 M
Price To Book Value xxxxxxxxxxxxxxx1.41

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx4.0 M
Capex % of Sales xxxxxxxxxxxxxxx14.57 %
Cost of Goods Sold xxxxxxxxxxxxxxx29 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx4 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Shaw and Partners

26/09/2024

1

Buy

$0.70

185.71%

Beamtree Holdings announced a second coding contract in Saudi Arabia worth $1.4m with the Centre for National Health Insurance.

Shaw and Partners notes the contract is for two years and will generate revenue of over $500k. The broker believes the contract "reinforces" annual recurring revenue for the company and the FY25 guidance.

Both coding and Saudi Arabia are highlighted as growth opportunities for Beamtree Holdings.

The Buy, High risk rating and 70c target are maintained.

FORECAST
Shaw and Partners forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.50 cents.
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.50 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

08/10/2024

1

Buy

$0.56

128.57%

Petra Capital predicts the share price for Beamtree Holdings will re-rate after a symbolic but strategic $0.5m contract win in the Kingdom of Saudi Arabia with the Centre for National Health Insurance (CNHI). Further downstream recurring revenue opportunities are expected.

As the CNHI is effectively the counterparty (payer) to the hospital network, the broker anticipates an on-ramp opportunity to deploy the company's performance indicators for coding quality (PICQ) tool inside around 400 hospitals in the Kingdom.

Target rises to 56c from 54c. Buy.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.30 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.70 cents.
Access Extra Coverage Research History >

BMT STOCK CHART

FNArena News on BMT

1
Australian Broker Call *Extra* Edition – Oct 08, 2024

Oct 08 2024 - Daily Market Reports
2
FNArena Corporate Results Monitor – 06-09-2024

Sep 06 2024 - Australia
3
Australian Broker Call *Extra* Edition – Aug 08, 2024

Aug 08 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Jun 11, 2024

Jun 11 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Feb 20, 2024

Feb 20 2024 - Daily Market Reports

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia